|
顯示項目 545351-545375 / 2310144 (共92406頁)
<< < 21810 21811 21812 21813 21814 21815 21816 21817 21818 21819 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2004 |
Lipoprotein-X Reduces Ldl Atherogenicity in Primary Biliary Cirrhosis by Preventing Ldl Oxidation
|
張博淵; 呂紹俊; 蘇大成; 周三芳; 廖朝崧; 李源德; CHANG, PO-YUAN; LU, SHAO-CHUN; SU, TA-CHEN; CHOU, SAN-FANG; LIAU, CHIAU-SUONG; LEE, YUAN-THE |
| 中國醫藥大學 |
2004 |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
(Po-Yuan Chang); (Shao-Chun Lu); (Ta-Chen Su); (San-Fang Chou); (Wen-Huei Huang); (Joel D. Morrisett); 陳珠璜(Chu-Huang Chen); (Chiau-Suong Liau); 李源德(Yuan-Teh, Lee) |
| 臺大學術典藏 |
2018-09-10T04:49:21Z |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
Chang, P.-Y. and Lu, S.-C. and Su, T.-C. and Chou, S.-F. and Huang, W.-H. and Morrisett, J.D. and Chen, C.-H. and Liau, C.-S. and Lee, Y.-T.; TA-CHEN SU |
| 臺大學術典藏 |
2020-02-06T08:11:33Z |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
Chang P.-Y.; SHAO-CHUN LU; Su T.-C.; Chou S.-F.; Huang W.-H.; Morrisett J.D.; Chen C.-H.; Liau C.-S.; Lee Y.-T.; Chang P.-Y.;Shao-Chun Lu;Su T.-C.;Chou S.-F.;Huang W.-H.;Morrisett J.D.;Chen C.-H.;Liau C.-S.;Lee Y.-T. |
| 臺大學術典藏 |
2020-09-28T02:48:05Z |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
Chang P.-Y.;Lu S.-C.;Ta-Chen Su;Chou S.-F.;Huang W.-H.;Morrisett J.D.;Chen C.-H.;Liau C.-S.;Lee Y.-T.; Chang P.-Y.; Lu S.-C.; TA-CHEN SU; Chou S.-F.; Huang W.-H.; Morrisett J.D.; Chen C.-H.; Liau C.-S.; Lee Y.-T. |
| 臺大學術典藏 |
2004 |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
Morrisett J.D.; Huang W.-H.; Chou S.-F.; Su T.-C.; Lu S.-C.; PO-YUAN CHANG; Chen C.-H.; Liau C.-S.; Lee Y.-T. |
| 高雄醫學大學 |
2004 |
Liposomal doxorubicin 治療引起的肢端紅斑症
|
薛強文;沈育如;陳國熏 |
| 義守大學 |
2017-04 |
Liposomal Encapsulation for Systemic Delivery of Propranolol via Transdermal Iontophoresis Improves Bone Microarchitecture in Ovariectomized Rats
|
Benjamin Teong;Shyh Ming Kuo;Wei-Hsin Tsai;Mei-Ling Ho;Chung-Hwan Chen;Han Hsiang Huang |
| 國家衛生研究院 |
2018-11 |
Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study
|
Chen, LT;Mercade, TM;Lee, KH;Lakatos, G;Wang-Gillam, A;Mirakhur, B;de Jong, F |
| 國家衛生研究院 |
2020-01 |
Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: Subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial
|
Macarulla Mercade, T;Chen, LT;Li, CP;Siveke, JT;Cunningham, D;Bodoky, G;Blanc, JF;Lee, KH;Dean, A;Belanger, B;Wang-Gillam, A |
| 國立成功大學 |
2020 |
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial
|
MacArulla, Mercad� T.;Chen, L.-T.;Li, C.-P.;Siveke, J.T.;Cunningham, D.;Bodoky, G.;Blanc, J.-F.;Lee, K.-H.;Dean, A.;Belanger, Belanger B.;Wang-Gillam, A. |
| 國家衛生研究院 |
2019-03-04 |
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial
|
Macarulla, T;Blanc, JF;Wang-Gillam, A;Chen, LT;Siveke, JT;Mirakhur, B;Chen, J;de Jong, FA |
| 國立成功大學 |
2019 |
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer – A subgroup analysis of the pivotal NAPOLI-1 trial
|
Macarulla, T.;Blanc, J.-F.;Wang-Gillam, A.;Chen, L.-T.;Siveke, J.T.;Mirakhur, B.;Chen, J.;de, Jong F.A. |
| 國家衛生研究院 |
2019-12-01 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
|
Bang, YJ;Li, CP;Lee, KH;Chiu, CF;Park, JO;Shan, YS;Kim, JS;Chen, JS;Shim, HJ;Rau, KM;Choi, HJ;Oh, DY;Belanger, B;Chen, LT |
| 國立成功大學 |
2020 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
|
Bang, Y.-J.;Li, C.-P.;Lee, K.-H.;Chiu, Chiu C.-F.;Park, J.O.;Shan, Y.-S.;Kim, J.S.;Chen, J.-S.;Shim, H.-J.;Rau, K.-M.;Choi, H.J.;Oh, D.-Y.;Belanger, Belanger B.;Chen, L.-T. |
| 中山醫學大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study
|
Chiu, TJ; Su, YY; Yang, SH; Li, CP; Bai, LY; Chiang, NJ; Chuang, SC; Shan, YS; Chan, DC; Chen, LT; Yen, CJ; Peng, CM; Chen, YY; Chen, JS; Chou, WC |
| 國家衛生研究院 |
2021-11-20 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
|
Chiu, TJ;Su, YY;Yang, SH;Li, CP;Bai, LY;Chiang, NJ;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Chen, YY;Chen, JS;Chou, WC |
| 國立成功大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
|
Chiu, T.-J.;Su, Y.-Y.;Yang, S.-H.;Li, C.-P.;Bai, L.-Y.;Chiang, N.-J.;Chuang, S.-C.;Shan, Y.-S.;Chan, D.-C.;Chen, L.-T.;Yen, C.-J.;Peng, C.-M.;Chen, Y.-Y.;Chen, J.-S.;Chou, W.-C. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients�� experience within a population-based study
|
Chiu T.-J.; Su Y.-Y.; SHIH-HUNG YANG; Li C.-P.; Bai L.-Y.; Chiang N.-J.; Chuang S.-C.; Shan Y.-S.; Chan D.-C.; Chen L.-T.; Yen C.-J.; Peng C.-M.; Chen Y.-Y.; Chen J.-S.; Chou W.-C. |
| 中山醫學大學 |
2016 |
Liposomal n-butylidenephthalide protects the drug from oxidation and enhances its antitumor effects in glioblastoma multiforme
|
YL, Lin; KF, Chang; XF, Huang; CL, Hung; SC, Chen; WR, Chao; KW, Liao; NM, Tsai |
| 國立交通大學 |
2019-04-03T06:35:34Z |
Liposomal n-butylidenephthalide protects the drug from oxidation and enhances its antitumor effects in glioblastoma multiforme
|
Lin, Yu-Ling; Chang, Kai-Fu; Huang, Xiao-Fan; Hung, Che-Lun; Chen, Shyh-Chang; Chao, Wan-Ru; Liao, Kuang-Wen; Tsai, Nu-Man |
| 臺大學術典藏 |
2021-07-07T02:12:42Z |
Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol
|
Huang S.-T.; YI-PING WANG; Chen Y.-H.; Lin C.-T.; Li W.-S.; Wu H.-C. |
| 臺大學術典藏 |
2022-03-04T06:10:52Z |
Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol
|
Huang S.-T.; Wang Y.-P.; Chen Y.-H.; CHIN-TARNG LIN; Li W.-S.; Wu H.-C. |
| 國家衛生研究院 |
2020-03-28 |
Liposomal TLR9 agonist combined with TLR2 agonist-fused antigen can modulate tumor microenvironment through dendritic cells
|
Shen, KY;Liu, HY;Yan, WL;Wu, CC;Lee, MH;Leng, CH;Liu, SJ |
| 臺大學術典藏 |
2021-06-22T02:01:33Z |
Liposomal vesicles-protein interaction: Influences of iron liposomes on emulsifying properties of whey protein
|
Yi, X.;Zheng, Q.;Pan, M.-H.;Chiou, Y.-S.;Li, Z.;Li, L.;Chen, Y.;Hu, J.;Duan, S.;Wei, S.;Ding, B.; Yi, X.; Zheng, Q.; Pan, M.-H.; Chiou, Y.-S.; Li, Z.; Li, L.; Chen, Y.; Hu, J.; Duan, S.; Wei, S.; Ding, B.; MIN-HSIUNG PAN |
顯示項目 545351-545375 / 2310144 (共92406頁)
<< < 21810 21811 21812 21813 21814 21815 21816 21817 21818 21819 > >>
每頁顯示[10|25|50]項目
|
